The investigational new drug (IND) application seeks permission from the FDA to administer endometrial regenerative cells to 10 patients having specific inclusion or exclusion criteria and will focus primarily on gathering safety information; however, markers of efficacy will also be evaluated.
The principal investigator of the proposed clinical trial is Michael Murphy from Indiana University.